Renaissance Technologies’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-452,000
| Closed | -$6.76M | – | 4592 |
|
|
2022
Q4 | $6.76M | Buy |
452,000
+291,400
| +181% | +$4.03M | 0.01% | 1322 |
|
|
2022
Q3 | $1.32M | Buy |
160,600
+37,200
| +30% | +$286K | ﹤0.01% | 2318 |
|
|
2022
Q2 | $810K | Buy |
123,400
+73,800
| +149% | +$357K | ﹤0.01% | 2848 |
|
|
2022
Q1 | $277K | Buy |
+49,600
| New | +$204K | ﹤0.01% | 3508 |
|
|
2021
Q3 | – | Sell |
-223,870
| Closed | -$1.48M | – | 4052 |
|
|
2021
Q2 | $1.48M | Buy |
223,870
+97,375
| +77% | +$671K | ﹤0.01% | 2448 |
|
|
2021
Q1 | $926K | Buy |
126,495
+29,995
| +31% | +$259K | ﹤0.01% | 2642 |
|
|
2020
Q4 | $557K | Buy |
+96,500
| New | +$552K | ﹤0.01% | 2775 |
|
|
2020
Q3 | – | Sell |
-64,868
| Closed | -$334K | – | 3862 |
|
|
2020
Q2 | $334K | Buy |
+64,868
| New | +$409K | ﹤0.01% | 2999 |
|
|
2017
Q3 | – | Sell |
-235,340
| Closed | -$5.22M | – | 3460 |
|
|
2017
Q2 | $5.22M | Sell |
235,340
-35,100
| -13% | -$276K | 0.01% | 1684 |
|
|
2017
Q1 | $1.6M | Sell |
270,440
-3,950
| -1% | -$28.5K | ﹤0.01% | 2355 |
|
|
2016
Q4 | $1.48M | Buy |
274,390
+14,850
| +6% | +$99K | ﹤0.01% | 2373 |
|
|
2016
Q3 | $2.31M | Buy |
259,540
+19,000
| +8% | +$179K | ﹤0.01% | 2105 |
|
|
2016
Q2 | $2.31M | Buy |
240,540
+31,050
| +15% | +$299K | ﹤0.01% | 2119 |
|
|
2016
Q1 | $1.93M | Buy |
209,490
+11,900
| +6% | +$118K | ﹤0.01% | 2242 |
|
|
2015
Q4 | $2.49M | Sell |
197,590
-11,590
| -6% | -$138K | 0.01% | 1975 |
|
|
2015
Q3 | $2.53M | Sell |
209,180
-2,900
| -1% | -$41.9K | 0.01% | 1855 |
|
|
2015
Q2 | $3.69M | Buy |
212,080
+84,480
| +66% | +$1.52M | 0.01% | 1645 |
|
|
2015
Q1 | $1.85M | Buy |
127,600
+60,020
| +89% | +$656K | ﹤0.01% | 1971 |
|
|
2014
Q4 | $568K | Buy |
67,580
+8,410
| +14% | +$76.9K | ﹤0.01% | 2387 |
|
|
2014
Q3 | $657K | Sell |
59,170
-75,179
| -56% | -$956K | ﹤0.01% | 2217 |
|
|
2014
Q2 | $2.46M | Buy |
134,349
+6,804
| +5% | +$88.5K | 0.01% | 1618 |
|
|
2014
Q1 | $1.91M | Sell |
127,545
-2,362
| -2% | -$42.4K | ﹤0.01% | 1793 |
|
|
2013
Q4 | $2.38M | Sell |
129,907
-968
| -0.7% | -$19.4K | 0.01% | 1661 |
|
|
2013
Q3 | $2.7M | Buy |
130,875
+9,139
| +8% | +$209K | 0.01% | 1518 |
|
|
2013
Q2 | $3.04M | Buy |
+121,736
| New | +$5.2M | 0.01% | 1359 |
|
Renaissance Technologies's AVEO Position: Q1 2023 in Review
Renaissance Technologies sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 452,000 shares — an estimated $6.76M sold.
Renaissance Technologies first reported a position in AVEO in Q2 2013 and held it in 25 quarters. The position peaked at $6.76M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Renaissance Technologies reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Renaissance Technologies sold 452,000 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $6.76M.
- Renaissance Technologies first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
- Renaissance Technologies's AVEO Pharmaceuticals, Inc. position peaked at $6.76M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.